Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer

K Nie, Z Zhang, C Zhang, C Geng, L Zhang, X Xu, S Liu… - Lung Cancer, 2018 - Elsevier
Objective To compare the efficacy and toxicity of osimertinib versus docetaxel-bevacizumab
as third-line treatment in EGFR T790M mutated NSCLC. Methods In this phase 3, open …
被引用次数：47 相关文章

Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer

K Nie, Z Zhang, C Zhang, C Geng, L Zhang… - Lung …, 2018 - lungcancerjournal.info
Objective To compare the efficacy and toxicity of osimertinib versus docetaxel-bevacizumab
as third-line treatment in EGFR T790M mutated NSCLC. Methods In this phase 3, open …

Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer

K Nie, Z Zhang, C Zhang, C Geng… - Lung cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Objective To compare the efficacy and toxicity of osimertinib versus docetaxel-bevacizumab
as third-line treatment in EGFR T790M mutated NSCLC. Methods In this phase 3, open …

Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.

K Nie, Z Zhang, C Zhang, C Geng, L Zhang… - Lung Cancer …, 2018 - europepmc.org
Objective To compare the efficacy and toxicity of osimertinib versus docetaxel-bevacizumab
as third-line treatment in EGFR T790M mutated NSCLC. Methods In this phase 3, open …

[引用][C] Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer

K Nie, Z Zhang, C Zhang, C Geng, L Zhang, X Xu, S Liu… - Lung Cancer, 2018 - cir.nii.ac.jp
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M
mutated non-small-cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報 …